Renibus Therapeutics Receives FDA Fast Track Designation for RBT-9 Treatment in COVID-19 DALLAS, Texas, June 23, 2020 (GLOBE NEWSWIRE) -- Renibus Therapeutics, Inc., a clinical-stage biotechnology company, announced today that it has been granted Fast Track designation by the FDA for...

Renibus Therapeutics Announces Publication of a Novel Stress Test for Assessing Antioxidant Defenses in Chronic Kidney Disease DALLAS, Texas, June 16, 2020 (GLOBE NEWSWIRE) -- Renibus Therapeutics, Inc., a clinical stage biotechnology company developing novel therapies for prevention and treatment of kidney diseases, today...

Renibus Therapeutics Announces Abstract Presentation at the 2020 European Renal Association – European Dialysis and Transplant Association (ERA-EDTA) Annual Congress Dallas, June 09, 2020 (GLOBE NEWSWIRE) -- Renibus Therapeutics, Inc, a clinical-stage biotechnology company, is pleased to announce that data highlighting the translation of the mechanism of action...